CD274 and cancer: Furthermore, PD-L1 expression by cancer cells may allow an Fc-active anti-PD-L1 antibody such as the IgG1 isotype avelumab to engage immune effector cells in the TME via Fc-FcR interactions, to affect a level of cytotoxic killing of PD-L1-expressing cancer cells.